Januvia Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Side Effects Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Sitagliptin phosphate

Indications/Uses

Monotherapy: Adjunct to diet & exercise to improve glycemic control in patients w/ type 2 DM. Combination therapy: Type 2 DM to improve glycemic control in combination w/ metformin, sulfonylurea, metformin + sulfonylurea, PPARγ agonist (eg, thiazolidinedione), metformin + PPARγ agonist or insulin (w/ or w/o metformin) when diet & exercise plus the single agent do not provide adequate glycemic control.

Click to view Januvia detailed prescribing information

Dosage/Direction for Use

Monotherapy or combination therapy w/ metformin, sulfonylurea, insulin (w/ or w/o metformin), PPARγ agonist, metformin + sulfonylurea or metformin + PPARγ agonist 100 mg daily. In combination therapy w/ sulfonylurea or insulin, lower dose of sulfonylurea or insulin should be considered.

Click to view Januvia detailed prescribing information

Overdosage

View Januvia overdosage for action to be taken in the event of an overdose.

Administration

May be taken with or without food.

Special Precautions

Not for use in type 1 DM or treatment of diabetic ketoacidosis, sulphonylurea- or insulin-induced hypoglycemia. Renal insufficiency. Pregnancy & lactation. Childn <18 yr. Elderly.

Click to view Januvia detailed prescribing information

Use In Pregnancy & Lactation

Click to view Januvia detailed prescribing information

Adverse Reactions

Abdominal pain, nausea, vomiting, diarrhea, dyspepsia, flatulence, hypoglycemia, headache, URTI.

Storage

View Januvia storage conditions for details to ensure optimal shelf-life.

Description

View Januvia description for details of the chemical structure and excipients (inactive components).

Action

View Januvia mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Antidiabetic Agents

ATC Classification

A10BH01 - sitagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.

Regulatory Classification

Presentation/Packing

Form

Januvia FC tab 100 mg

Packing/Price

28's

Form

Januvia FC tab 25 mg

Packing/Price

28's

Form

Januvia FC tab 50 mg

Packing/Price

28's

Januvia

sitagliptin

Manufacturer:

Merck Sharp & Dohme

Distributor:

Zuellig Pharma